Open AccessExfoliative dermatitis as a complication of drug eruption associated with COVID-19
Author(s) -
Е. В. Файзуллина,
И. М. Хисматулина,
R.M. Abdrakhmanov,
V V Usmanov
Publication year - 2021
Publication title -
kazanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2587-9359
pISSN - 0368-4814
DOI - 10.17816/kmj2021-551
Subject(s) - exfoliative dermatitis , medicine , hydroxychloroquine , dermatology , drug eruption , comorbidity , diabetes mellitus , pneumonia , concomitant , erythroderma , disease , complication , drug , covid-19 , surgery , pharmacology , infectious disease (medical specialty) , endocrinology
We report a clinical case of exfoliative dermatitis associated with a novel coronavirus disease. A patient with moderate COVID-19 and decompensation of insulin-dependent diabetes mellitus, hypertension and obesity developed a generalized drug eruption. Treatment of coronavirus infection included drugs associated with the frequent development of skin allergic reactions: third-generation cephalosporin and hydroxychloroquine. In this clinical case, the patient had a generalized form of exfoliative dermatitis with moderate COVID-19. Thus, the generalization of drug eruption occurred with a decrease in the viral pneumonia foci area and was accompanied by repeated deterioration of general condition of the patient. Skin rashes resolved in the correction of concomitant pathology. Erythroderma has a benign course in hemostatic disorders and the use of systemic glucocorticosteroids, hyperglycemia therapy. For managing such patients, it is important to use an integrated approach, providing both the treatment of the underlying disease and the correction of comorbidity and complications. This is relevant for both dermatologist-venereologist and specialists involved in the treatment of COVID-19.